The mission of the Society is to improve patient care and outcomes by facilitating implementation of functional assays into clinical care. The purposes are to foster research and development of functional precision medicine solutions across medicine; to accelerate the dissemination of new and relevant research findings among interested parties; to promote education and training about functional precision medicine; to foster solutions for clinical testing of functional precision medicine approaches; and to improve efficiency of adoption of functional precision medicine solutions through interaction with academia, regulatory bodies, industry, and patients.Become a Member
The SFPM is excited to announce that in partnership with European Hematology Association, we will be organizing a Precision Medicine Meeting; Bridging between functional and genomic precision medicine, to be held September 25-27, 2024, Copenhagen, Denmark. We will continue to post updates as they become available.
Do you want to help shape the future of the SFPM? Self-nominate for a board position today and lend your experience and input!
Open positions for this election cycle include
Positions will be filled by vote of the Professional or Associate members in good standing. You must be a Professional or Associate member to view the form and apply.
The SFPM arose out of recognition of the unmet need in matching cancer patients to the therapies best suited for them. Through the use of functional assays, we hope to bridge the gap between patients and the treatments best suited for their cancer. This is possible through research, communication, and collaboration amongst our members and with outreach to the cancer therapy community as a whole. To further the mission, we offer our members the following exclusive benefits
Applications for membership may be submitted at any time during the year. We look forward to having you onboard!
Come join us for our Virtual Monthly Seminar which will bring together a unique mix of pharmaceutical, academic and technology leaders, the series should not be missed for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
Wednesday, October 11, 2023
11:30 AM EST
Meeting URL: dfci.zoom.us
Meeting ID: 932 5793 1032 | Password: 153772
Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked. Check out our news archive for all past stories and posts.
Here we describe a case study of a patient with low grade serious ovarian cancer who underwent two rounds of chemotherapy and two surgeries. Despite this, her cancer progressed to the point that she was in rapid decline and entering hospice care. Drug testing on tumor organoids derived from the second surgical resection showed exceptional sensitivity to the BTK inhibitor ibrutinib. Although ibrutinib is not FDA approved for the treatment of ovarian cancer, the tumor board and oncologist recommended and requested its off-label use for this case. Following daily ibrutinib as a mono therapy, the patient exhibited a dramatic and prolonged clinical response, resulting in stable disease for >24 months.
Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.
Join us October 12 - 13, 2023 as 50+ speakers, 400+ participants, and 20+ countries come together for one goal; to improve patient care and outcomes by promoting the development and adoption of Precision Medicine! Registration is open!
Drug sensitivity testing including a broad panel of standard and off-label drugs showed that 50% of the patients showed progression-free-survival after 2 months of 3D organoid guided treatment. The primary end-point was set to 40%. The trial was conducted at University Hospital of Southern Denmark, Vejle and published in Journal of Experimental & Clinical Cancer Research.
The current issue of Nature Reviews Cancer features on its cover a personal perspective on the fight against rare cancers. One part of the story of this features the use of an agnostic drug-repurposing screen to do functional precions medicine. This revealed vulnerabilities that were not predicted by the transcriptome, but which helped not only elucidate some important cell biology pathways in the toumor, but have laid the foundation for a clinical trial
The SFPM is growing, and we need financial support. While we collect annual individual membership dues, these only fund a fraction of our needs. To plan for the future, the SFPM must secure a stable financial basis from which to plan. Even though the Board is made up of unpaid volunteers, we nonetheless have significant costs to defray, particularly with respect to annual meetings and administrative support.
Contributions from all tiers will be recognized by name on the SFPM website, however, contributions at the Precision tier will receive preferred logo placement and recognition on the SFPM website, logo and name recognition at each monthly seminar, and institution name and logo prominently displayed at our annual meeting and on meeting marketing materials. Precision tier supporters will also receive ten (10) complimentary memberships to be distributed amongst their institutions. Functional tier supporters will receive name and logo recognition during at least six of our monthly seminars as well as name and logo recognition on our website. Functional tier supporters will also receive five (5) complimentary memberships to be distributed amongst their institutions. Advocate tier supporters will receive name and logo recognition on our website and one (1) complimentary membership. We hope you agree with us that “the future is functional”, and that the SFPM is getting us there faster.